Association Between Cabozantinib and Skin Reactions in Urothelial Carcinoma

Share this content:

the Cancer Therapy Advisor take:

Researchers set out to better understand the relationship and frequency skin reactions in patients with urothelial carcinoma who are being treated only cabozantinib.

The study was based in a single institution (the Clinical Research Center at the National Institutes of Health) and included 41 adult patients with metastatic, progressive urothelial carcinoma who were enrolled in a phase 2 clinical trial and receiving cabozantinib as monotherapy.

The patients were monitored for skin reactions after treatment between October 2012 and June 2014. The patients were evaluated by the primary oncology team and, when necessary, referred to a dermatologist. The researchers found that of the group of 41 evaluable patients, 73% (30 patients) developed at least one cutaneous toxic effect.

The adverse events included 22 patients with hand-foot reactions (54%), 18 pateints with generalized pigment dilution and/or hair depigmentation (44%), 8 patients with xerosis (20%), 6 patients with scrotal erythema/ulceration (15%), and 5 patients with nail splinter hemorrhages (12%).

Two or more cutaneous adverse events were seen in 18 patients (44%). Fifty-seven percent of patients (17 patients) had reactions within the first month of treatment, and 80% (24 patients) within the second month. The researchers concluded that cabozantinib monotherapy is associated with cutaneous adverse reactions in many patients and if the oncology team can detect reactions early and treat them effectively it may assist in a patients’ adherence to the treatment regimen. 

Association Between Cabozantinib and Skin Reactions in Patients with Urothelial Carcinoma
The relationship and frequency skin reactions in urothelial carcinoma who are being treated only cabozantinib evaluated.
Researchers conducted this study to assess the frequency and spectrum of skin reactions in patients with urothelial carcinoma receiving cabozantinib as monotherapy. They concluded that in most patients, cabozantinib monotherapy is associated with 1 or more cutaneous adverse events.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs